Long-acting Inhalable Chitosan-coated Poly(lactic-co-glycolic Acid) Nanoparticles Containing Hydrophobically Modified Exendin-4 for Treating Type 2 Diabetes

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2013 Aug 27

PMID 23976850

Citations 16

Authors

Changkyu Lee

Ji Su Choi

Insoo Kim

Kyung Taek Oh

Eun Seong Lee

Eun-Seok Park

Kang Choon Lee

Yu Seok Youn

Affiliations

Soon will be listed here.

Abstract

Inhalable glycol chitosan-coated poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing palmitic acid-modified exendin-4 (Pal-Ex4) (chitosan Pal-Ex4 PLGA NPs) were prepared and characterized. The surface morphology, particle size, and zeta potential of chitosan Pal-Ex4 PLGA NPs were investigated, and the adsorption and cytotoxicity of chitosan Pal-Ex4 PLGA NPs were evaluated in human lung epithelial cells (A549). Finally, the lung deposition characteristics and hypoglycemia caused by chitosan Pal-Ex4 PLGA NPs were evaluated after pulmonary administration in imprinting control region (ICR) and type 2 diabetic db/db mice. Results showed that chitosan Pal-Ex4 PLGA NPs were spherical, compact and had a diameter of ~700 nm and a positive surface charge of +28.5 mV Chitosan-coated PLGA NPs were adsorbed onto A549 cells much more so than non-coated PLGA NPs. Pal-Ex4 release from chitosan-coated PLGA NPs was delayed by as much as 1.5 days as compared with chitosan-coated Ex4 PLGA NPs. In addition, chitosan-coated PLGA NPs remained in the lungs for ~72 hours after pulmonary administration, whereas most non-coated PLGA NPs were lost at 8 hours after administration. Furthermore, the hypoglycemic efficacy of inhaled chitosan Pal-Ex4 PLGA NPs was 3.1-fold greater than that of chitosan Ex4 PLGA NPs in db/db mice. The authors believe chitosan Pal-Ex4 PLGA NPs have considerable potential as a long-acting inhalation delivery system for the treatment of type 2 diabetes.

Citing Articles

Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery.

Maloney Norcross S, Levin L, Hickey A, Hill D Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770469 PMC: 11728674. DOI: 10.3390/ph17121628.

Chitosan nanoparticle toxicity: A comprehensive literature review of and assessments for medical applications.

Zoe L, David S, Rajabalaya R Toxicol Rep. 2024; 11:83-106.

PMID: 38187113 PMC: 10767636. DOI: 10.1016/j.toxrep.2023.06.012.

Alveolar macrophage phagocytosis-evading inhaled microgels incorporating nintedanib-PLGA nanoparticles and pirfenidone-liposomes for improved treatment of pulmonary fibrosis.

Lee W, Lee H, Kim J, Jung Y, Choi E, Jeong J Bioact Mater. 2023; 33:262-278.

PMID: 38076650 PMC: 10708963. DOI: 10.1016/j.bioactmat.2023.11.005.

Nanocarrier system: An emerging strategy for bioactive peptide delivery.

Zhang X, Li X, Zhao Y, Zheng Q, Wu Q, Yu Y Front Nutr. 2022; 9:1050647.

PMID: 36545472 PMC: 9760884. DOI: 10.3389/fnut.2022.1050647.

Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections.

Sabuj M, Islam N Nanoscale Adv. 2022; 3(14):4005-4018.

PMID: 36132845 PMC: 9419283. DOI: 10.1039/d1na00205h.

References

Chuang V, Kragh-Hansen U, Otagiri M . Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res. 2002; 19(5):569-77. DOI: 10.1023/a:1015396825274. View

Patton J, Fishburn C, Weers J . The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2005; 1(4):338-44. DOI: 10.1513/pats.200409-049TA. View

Tahara K, Yamamoto H, Kawashima Y . Cellular uptake mechanisms and intracellular distributions of polysorbate 80-modified poly (D,L-lactide-co-glycolide) nanospheres for gene delivery. Eur J Pharm Biopharm. 2010; 75(2):218-24. DOI: 10.1016/j.ejpb.2010.03.013. View

Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T . Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999; 62(1-2):279-87. DOI: 10.1016/s0168-3659(99)00048-6. View

Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y . Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release. 2005; 102(2):373-81. DOI: 10.1016/j.jconrel.2004.10.010. View

Kim H, Park H, Lee J, Kim T, Lee E, Oh K . Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials. 2010; 32(6):1685-93. DOI: 10.1016/j.biomaterials.2010.10.045. View

Kim H, Lee J, Kim T, Lee E, Oh K, Lee D . Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res. 2011; 28(8):2008-19. DOI: 10.1007/s11095-011-0427-4. View

Lee J, Lee C, Kim I, Ryong Moon H, Kim T, Oh K . Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia. Int J Pharm. 2012; 424(1-2):50-7. DOI: 10.1016/j.ijpharm.2011.12.050. View

Censi R, Di Martino P, Vermonden T, Hennink W . Hydrogels for protein delivery in tissue engineering. J Control Release. 2012; 161(2):680-92. DOI: 10.1016/j.jconrel.2012.03.002. View

10.

Grenha A, Grainger C, Dailey L, Seijo B, Martin G, Remunan-Lopez C . Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci. 2007; 31(2):73-84. DOI: 10.1016/j.ejps.2007.02.008. View

11.

Park J, Saravanakumar G, Kim K, Kwon I . Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev. 2009; 62(1):28-41. DOI: 10.1016/j.addr.2009.10.003. View

12.

Choi M, Cho M, Han B, Hong J, Jeong J, Park S . Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice. Toxicol Lett. 2010; 199(2):144-52. DOI: 10.1016/j.toxlet.2010.08.016. View

13.

Nafee N, Schneider M, Schaefer U, Lehr C . Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm. 2009; 381(2):130-9. DOI: 10.1016/j.ijpharm.2009.04.049. View

14.

Chae S, Choi Y, Son S, Jung S, Lee D, Lee K . The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release. 2010; 144(1):10-6. DOI: 10.1016/j.jconrel.2010.01.024. View

15.

Makhlof A, Werle M, Tozuka Y, Takeuchi H . Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin. Int J Pharm. 2010; 397(1-2):92-5. DOI: 10.1016/j.ijpharm.2010.07.001. View

16.

Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y . Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm. 2009; 382(1-2):198-204. DOI: 10.1016/j.ijpharm.2009.07.023. View

17.

Sogias I, Williams A, Khutoryanskiy V . Why is chitosan mucoadhesive?. Biomacromolecules. 2008; 9(7):1837-42. DOI: 10.1021/bm800276d. View

18.

Bhattarai N, Gunn J, Zhang M . Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev. 2009; 62(1):83-99. DOI: 10.1016/j.addr.2009.07.019. View

19.

LAUWERYNS J, Baert J . Alveolar clearance and the role of the pulmonary lymphatics. Am Rev Respir Dis. 1977; 115(4):625-83. DOI: 10.1164/arrd.1977.115.4.625. View

20.

Lee J, Lee C, Kim T, Lee E, Shin B, Chi S . Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a long-acting anti-diabetic inhalation system. J Control Release. 2012; 161(3):728-34. DOI: 10.1016/j.jconrel.2012.05.029. View